Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome

DOI QR Code

Chakraborty, Rajshekhar (Department of Internal Medicine, Queens Hospital Center, Icahn School of Medicine at Mount Sinai) ;
Mukkamalla, Shiva Kumar Reddy (Department of Internal Medicine, Queens Hospital Center, Icahn School of Medicine at Mount Sinai) ;
Singam, Kranthi (Department of Internal Medicine, Queens Hospital Center, Icahn School of Medicine at Mount Sinai) ;
Calderon, Natalia (Department of Internal Medicine, Queens Hospital Center, Icahn School of Medicine at Mount Sinai)

Toubai T, Tanaka J, Ota S, et al. Allogeneic bone marrow transplantation from an unrelated donor for the treatment of chronic myelogenous leukemia in blast crisis in a patient with Kleinfelter's syndrome. Leuk Lymphoma 2004;45:829-831. https://doi.org/10.1080/10428190310001607188
Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA; UK Clinical Cytogenetics Group. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 2005;97:1204-1210. https://doi.org/10.1093/jnci/dji240
Alimena G, Billstrom R, Casalone R, Gallo E, Mitelman F, Pasquali F. Cytogenetic pattern in leukemic cells of patients with constitutional chromosome anomalies. Cancer Genet Cytogenet 1985;16:207-218. https://doi.org/10.1016/0165-4608(85)90047-0
Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105:2281-2286. https://doi.org/10.1182/blood-2004-06-2208
Huntly BJ, Guilhot F, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003;102:2205-2212. https://doi.org/10.1182/blood-2002-09-2763

Sex chromosome changes in leukemia: cytogenetics and molecular aspects vol.23, pp.3, 2014, https://doi.org/10.1080/10245332.2017.1375063